CARsgen Therapeutics Holdings Limited (2171.HK)

Name: CARsgen Therapeutics Holdings Limited Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-04-09

Latest Quarter

2026-04-09

Revenue

$0.0

Net Income

$0.0

Operating Margin

N/A

Free Cash Flow

$0.0

Debt / Assets

39.7%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for CARsgen Therapeutics Holdings Limited (2171.HK).
Income Statement (Quarterly)	2026-04-09	2025-12-31	2025-06-30	2025-03-31
Revenue	0	73,454,718	54,739,806	0
Cost of Revenue	0	23,719,557	34,951,797	0
Gross Profit	0	49,735,160	19,788,008	0
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	0	29,364,778	42,078,789	0
Operating Expenses	0	142,579,897	171,053,168	0
Operating Income	0	-92,844,735	-151,265,159	0
Interest Expense	0	3,769,051	3,291,198	0
Income Before Tax	0	-26,966,469	-81,080,136	0
Income Tax Expense	0	0	0	0
Net Income	0	-22,145,268	-80,926,532	0
Per Share
EPS	-0.14	-0.04	-0.15	-0.07
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for CARsgen Therapeutics Holdings Limited (2171.HK).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	122,409,727	39,425,000	0	0	25,813,000
Cost of Revenue	73,263,481	24,678,000	0	0	0
Gross Profit	49,146,246	14,747,000	0	0	25,813,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	65,692,629	52,024,000	133,312,000	46,822,000	65,816,000
Operating Expenses	278,300,896	822,938,000	767,649,000	802,281,000	611,802,000
Operating Income	-229,154,650	-808,191,000	-767,649,000	-881,297,000	-573,905,000
Interest Expense	6,718,497	5,713,000	0	15,521,000	10,869,000
Income Before Tax	-100,243,652	-797,786,000	-747,387,000	-890,952,000	-4,736,778,000
Income Tax Expense	0	346,000	407,000	1,295,000	7,645,000
Net Income	-95,328,248	-798,132,000	-747,794,000	-892,247,000	-4,744,423,000
Per Share
EPS	-0.17	-1.44	-1.34	-1.62	-8.36
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for CARsgen Therapeutics Holdings Limited (2171.HK).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	1,123,894,622	1,479,058,000	1,849,752,000	2,268,036,000
Short Term Investments	0	839,000	1,128,000	6,309
Net Receivables	31,608,516	27,273,000	0	0
Inventory	7,141,053	6,926,000	683,000	0
Total Current Assets	1,178,591,014	1,530,275,000	1,873,088,000	2,300,639,000
Property Plant Equipment	97,886,859	123,949,000	361,390,000	436,863,000
Goodwill and Intangibles	0	2,943,000	8,660,000	21,106,000
Total Assets	1,292,688,806	1,673,034,000	2,257,214,000	2,762,819,000
Liabilities
Account Payables	0	0	0	0
Short Term Debt	12,847,493	33,728,000	14,752,000	21,984,000
Total Current Liabilities	205,544,899	254,007,000	196,217,000	171,004,000
Long Term Debt	48,356,679	132,694,000	70,468,000	97,461,000
Total Liabilities	513,018,387	616,327,000	455,514,000	289,645,000
Shareholders Equity
Retained Earnings	0	-8,987,961,000	-8,189,829,000	-7,442,035,000
Total Shareholders Equity	779,670,418	1,056,707,000	1,801,700,000	2,473,174,000

Balance sheet annual history for CARsgen Therapeutics Holdings Limited (2171.HK).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	1,123,894,622	1,479,058,000	1,849,752,000	2,268,036,000	691,284,000
Short Term Investments	0	839,000	1,128,000	6,309	2,315,654,000
Net Receivables	31,608,516	27,273,000	0	0	0
Inventory	7,141,053	6,926,000	683,000	0	0
Total Current Assets	1,178,591,014	1,530,275,000	1,873,088,000	2,300,639,000	3,070,853,000
Property Plant Equipment	97,886,859	123,949,000	361,390,000	436,863,000	384,766,000
Goodwill and Intangibles	0	2,943,000	8,660,000	21,106,000	26,919,000
Total Assets	1,292,688,806	1,673,034,000	2,257,214,000	2,762,819,000	3,505,635,000
Liabilities
Account Payables	0	0	0	0	0
Short Term Debt	12,847,493	33,728,000	14,752,000	21,984,000	233,358,000
Total Current Liabilities	205,544,899	254,007,000	196,217,000	171,004,000	389,172,000
Long Term Debt	48,356,679	132,694,000	70,468,000	97,461,000	104,687,000
Total Liabilities	513,018,387	616,327,000	455,514,000	289,645,000	508,975,000
Shareholders Equity
Retained Earnings	0	-8,987,961,000	-8,189,829,000	-7,442,035,000	0
Total Shareholders Equity	779,670,418	1,056,707,000	1,801,700,000	2,473,174,000	2,996,660,000

Cash flow quarterly history for CARsgen Therapeutics Holdings Limited (2171.HK).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-95,328,248	-798,132,000	-747,387,000	-890,952,000
Depreciation & Amortization	28,732,610	79,555,000	87,395,000	81,533,000
Stock Based Compensation	0	9,089,000	14,458,000	43,995,000
Change in Working Capital	0	-29,615,000	211,375,000	43,482,000
Operating Cash Flow	-230,768,764	-409,690,000	-454,935,000	-643,048,000
Investing Activities
Capital Expenditure	230,768,764	-19,574,000	-9,549,000	-138,614,000
Investments	0	0	-8,835,000	-138,614,000
Investing Cash Flow	-2,809,358	12,522,000	39,251,000	2,386,990,000
Financing Activities
Debt Repayment	-86,696,580	72,859,000	-24,072,000	-327,748,000
Common Stock Issued/Repurchased	-83,774,224	-50,272,000	6,610,000	10,505,000
Dividends Paid	0	0	0	0
Financing Cash Flow	-108,832,458	18,457,000	-22,142,000	-236,514,000
Summary
Free Cash Flow	0	-429,264,000	-464,484,000	-781,662,000
Net Change in Cash	-289,900,367	-370,694,000	-418,284,000	1,576,752,000

Cash flow annual history for CARsgen Therapeutics Holdings Limited (2171.HK).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-95,328,248	-798,132,000	-747,387,000	-890,952,000	-4,744,423,000
Depreciation & Amortization	28,732,610	79,555,000	87,395,000	81,533,000	52,446,000
Stock Based Compensation	0	9,089,000	14,458,000	43,995,000	13,504,000
Change in Working Capital	0	-29,615,000	211,375,000	43,482,000	13,379,000
Operating Cash Flow	-230,768,764	-409,690,000	-454,935,000	-643,048,000	-512,322,000
Investing Activities
Capital Expenditure	230,768,764	-19,574,000	-9,549,000	-138,614,000	-178,453,000
Investments	0	0	-8,835,000	-138,614,000	-175,841,000
Investing Cash Flow	-2,809,358	12,522,000	39,251,000	2,386,990,000	-2,471,321,000
Financing Activities
Debt Repayment	-86,696,580	72,859,000	-24,072,000	-327,748,000	-146,865,000
Common Stock Issued/Repurchased	-83,774,224	-50,272,000	6,610,000	10,505,000	2,576,082,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	-108,832,458	18,457,000	-22,142,000	-236,514,000	2,674,032,000
Summary
Free Cash Flow	0	-429,264,000	-464,484,000	-781,662,000	-690,775,000
Net Change in Cash	-289,900,367	-370,694,000	-418,284,000	1,576,752,000	-351,685,000